Overview of funded FFOR projects

Targeting Cell Types and Circuits to Treat OCD

OCD has lagged behind other neuropsychiatric disorders in discovery of new treatments due to lack of clear molecular candidates for new drug development and lack of sufficient understanding of the malfunctioning neural circuits. FFOR is now attacking this problem directly by discovering de novo mutations of large effect size. While these new targets are being identified, the FFOR Mouse Circuit Consortium is identifying the neural circuits and cellular components that underlie OCD-relevant behaviors, so that we can rapidly deploy these new genetic discoveries into the circuits and cell types most relevant to processes disrupted in OCD. Although insights regarding dysfunctional circuits in OCD have been obtained via human neuroimaging studies, they are inherently limited due to lack of cellular resolution and inability to directly test cause and effect.

Recent technological advances now allow us to directly monitor and manipulate specific cell types and circuits in mice to test causality and mechanism, providing a crucial bridge between neural functions relevant to human symptoms and genes. These mechanistic studies will ultimately allow us to determine how identified genetic mutations alter function in key circuits, and pave the way towards development of novel circuit-specific pharmacological or neural stimulation approaches.

The FFOR Mouse Circuit Consortium has 3 overarching goals to support this endeavor by coordinating and integrating research efforts across our four sites.

•  GOAL 1: Dissect circuits underlying key neural functions relevant to OCD pathology and treatment. 

•  GOAL 2: Identify cell-types crucial to OCD pathology and treatment. 

• GOAL 3: Perform preclinical studies to facilitate the work of the FFOR rTMS and DBS research groups.  

Accelerated Transcranial Magnetic Stimulation: Optimizing a New Treatment for OCD

Obsessive compulsive disorder (OCD) is a common neuropsychiatric condition that affects approximately 2% of the population and is often highly debilitating. Unlike many diagnoses in other areas of medicine, OCD is not a single disease: it is expressed differently from person to person, and it is likely that there are multiple forms of OCD caused by distinct disease processes. Medications and therapy are the standard treatments; however, many patients show only a partial improvement, and more than 25% of patients show no improvement with these treatments. New interventions are urgently needed. Repetitive transcranial magnetic stimulation (rTMS) is a promising alternative, using powerful, focused magnetic pulses to stimulate two brain areas, the dorsomedial prefrontal cortex and the orbitofrontal cortex. Patients often show a strong response to stimulating one target but not the other. It is not well understood why some patients respond, while others do not. Recent evidence suggests that an accelerated course of 10x daily rTMS for five days not only accelerates treatment response but also yields markedly higher remission rates in depression, and the same principle may apply in cases of OCD. Our project will optimize and test a new accelerated rTMS protocol for treating OCD. In parallel, we will apply methods we have developed to discover circuit subtypes of OCD and develop prognostic neuroimaging biomarkers for predicting differential treatment response to rTMS targeting the orbitofrontal or dorsomedial prefrontal cortex.

Dissection of circuit-typed OCD to optimize a next generation deep brain stimulation strategy

Deep Brain Stimulation (DBS) can provide symptomatic relief in many OCD patients refractory to conventional medical and cognitive therapies. However, as many as 40% of patients do not respond to this form of invasive neuromodulation, and most patients will still have significant residual symptoms.

The lack of consistent benefit with existing forms of DBS for OCD is likely multi-factorial, due to:

1. heterogeneity in the indication

2. suboptimal targeting of relevant circuits

3. lack of sufficient target engagement with conventional stimulation protocols

Here, we aim to overcome these barriers by collaborating with our FFOR partners to identify circuit-defined OCD biotypes responsive to neuromodulation, i.e. rTMS. We will then utilize a novel approach to utilizing stereoencephalography (sEEG) to map neural networks underlying OCD symptoms and identify potentially novel DBS targets. These studies will then guide the development of computationally informed stimulation protocols that can be incorporated into next-generation neurostimulation devices. A multidisciplinary team of neurophysiologists, data scientists, psychiatrists, and neurosurgeons based at Stanford and UCSF will be leading this project in collaboration with cognitive researchers at UCLA and computational neuroscientists at Mayo Clinic. The study will culminate in a randomized control early feasibility trial of our novel DBS approach for treating refractory OCD.

[Project Headline]

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Accumsan in nisl nisi scelerisque eu. Non arcu risus quis varius quam. Felis eget velit aliquet sagittis id consectetur purus ut faucibus. Lacus vel facilisis volutpat est velit egestas dui. Donec ultrices tincidunt arcu non sodales neque. Mauris pharetra et ultrices neque ornare. Lobortis scelerisque fermentum dui faucibus in ornare quam. Tempus iaculis urna id volutpat lacus laoreet non curabitur. Sem nulla pharetra diam sit amet nisl suscipit adipiscing bibendum. Enim nulla aliquet porttitor lacus luctus accumsan tortor posuere. Consectetur adipiscing elit ut aliquam purus sit amet. Adipiscing elit pellentesque habitant morbi tristique senectus et.

Pulvinar pellentesque habitant morbi tristique senectus et netus et. Neque gravida in fermentum et sollicitudin. Diam maecenas ultricies mi eget mauris pharetra et ultrices neque. Sed viverra tellus in hac habitasse. Pharetra et ultrices neque ornare aenean euismod.

• Lorem ipsum dolor sit amet, consectetur adipiscing elit.

• Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

• Adipiscing elit pellentesque habitant morbi tristique senectus.